Indications for: ARAKODA
Swallow whole. Take with food. ≥18yrs: initially 200mg once daily starting 3 days before travel, then 200mg once weekly starting 7 days after last loading dose while in endemic area, then 200mg taken once, 7 days after last maintenance dose.
<18yrs: not established.
G6PD deficiency or unknown status. Nursing mothers when infant is G6PD deficient or status unknown. History of or current psychotic disorders.
Must test for G6PD deficiency prior to initiation. Monitor for hemolysis; discontinue if occurs. NADH-dependent methemoglobin reductase deficiency; monitor and discontinue if signs of methemoglobinemia occur. Consider discontinuing if psychotic symptoms (eg, hallucinations, delusions, disorganized thinking/behavior) occur. Discontinue if hypersensitivity reactions occur. Renal or hepatic impairment: monitor. Exclude pregnancy status prior to initiation. Pregnancy: not recommended; if detected during therapy, discontinue and switch to alternatives. Advise females of reproductive potential to use effective contraception during and for 3 months after last dose. Nursing mothers: not recommended (during and for 3 months after last dose) in G6PD-deficient infant or status unknown.
Avoid concomitant OCT2 and MATE substrates (eg, dofetilide, metformin); if unavoidable, monitor and consider dose reduction of substrate if needed.
Headache, dizziness, back pain, diarrhea, nausea, vomiting, increased ALT, motion sickness, insomnia, depression, abnormal dreams, anxiety; hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions.
Generic Drug Availability: